Struthers Richard Scott, PRES, CEO, reported a transaction classified as grant at Crinetics Pharmaceuticals, Inc. involving 89000.000000 shares for an estimated $0.00. Reported holdings after the transaction were 346485.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
Form 4 relationship flags and nearby filing context
President & CEO
The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on M…
The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 20, 2025.
0 other filings
0 recent txs